Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer

The oncologist

article

Chelsea K. Osterman¹  Shun Yu²  Vivek Narayan²  Thomas J. Guzzo³  Elizabeth R. Plimack⁴  David J. Vaughn³  Chunkit Fung⁵  Ronac Mamtani²  Dilip S. Babu⁵  Daniel M. Geynisman⁴  Bianca Lewis⁴  Robert A. Somer⁶  Arjun V. Balar⁷  Matthew R. Zibelman⁴  Elizabeth A. Guancial⁸  Gianna Antinori⁶ 

[1] University of North Carolina Medical Center;Abramson Cancer Center, University of Pennsylvania;Department of Urology, Hospital of the University of Pennsylvania;Fox Chase Cancer Center;University of Rochester Medical Center;MD Anderson Cancer Center at Cooper;Langone Medical Center, New York University;Florida Cancer Specialists and Research Institute

关键词: Muscle-invasive bladder cancer;    Neoadjuvant chemotherapy;    Cisplatin;    Nephrotoxicity;   

DOI  :  10.1634/theoncologist.2018-0561

学科分类：地质学

来源: AlphaMed Press Incorporated

【 摘 要 】

Neoadjuvant cisplatin-based chemotherapy (NAC; 70 mg/m 2 ) is standard of care for muscle-invasive bladder carcinoma (MIBC). Many patients (pts) cannot receive cisplatin because of renal impairment, and administration of cisplatin 35 mg/m 2 on day 1 + 8 or 1 + 2 (i.e., split schedule) is a commonly used alternative. In this retrospective analysis, we compared complete (pT0) and partial ( p  = .21), corresponding to an odds ratio for pT0 of 0.45 (95% CI, 0.16–1.31) with SS cisplatin. Split schedule cisplatin was associated with numerically but not statistically significant lower pathologic response rates relative to full dose.

【 授权许可】

CC BY|CC BY-NC